Over 13,000 new cases of prostate cancer were diagnosed in South Africa in 2020.1
Digital rectal examination and a blood test screening for serum prostate-specific antigen can help to detect prostate cancer in asymptomatic men early, whilst it can still be cured.2
Routine population screening for prostate cancer is not currently recommended in South Africa but informed, patient-based screening is:3
- From the age of 40 in those with a positive family history of prostate and/or breast cancer in a first-degree relative.
- From the age of 50 years in all other males.
- Patients with a history of lower urinary tract symptoms (LUTS) and/or clinical suspicion of prostate cancer regardless of age.
The goals of treatment for prostate cancer are to delay disease progression, improve quality of life and increase survival.2
The choice of treatment is dependent on informed patient decision-making, availability of treatment, cost and complications.2
Cancer patients often face high out-of-pocket medical costs. These extra costs can prevent or delay access to important medical care.4
One of the priorities in the National Cancer Strategic Framework for South Africa is to improve access to treatment by reducing financial, geographic, logistical and socio-cultural barriers.4
Sandoz South Africa has a growing portfolio of oncology medications and we are committed to improving both affordability and access to high-quality generics medications for both South African cancer patients and healthcare providers.5
Globocan 2020. South Africa. International Agency for Research on Cancer. March 2021
Anderson D, Barnes R, Bida M, et al. South African Prostate Cancer Guidelines – Draft Version. 2017
Draft PMB Benefit Guideline: Prostate Cancer. Council of Medical Schemes. 31 Mar 2020
Department of Health, Republic of South Africa. National Cancer Strategic Framework for South Africa 2017 – 2022
Sandoz SA (Pty) Ltd. Data on File. Sandoz Oncology. Closer to Solutions. 2021